Pharmaceuticals & Biotech Canadian Community

Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more

BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more

Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more

Cybin is pushing a psychedelic-based depression treatment that may work with only one or two sessions, which could make it easier to use than some existing options. Fast-track attention from U.S. regulators and upcoming trial results in depression and anxiety could be the next big make-or-break moments.Read more

Verano bets that cannabis demand jumps as more states loosen rules, and its early footprint and efficient operations could help it grow faster than rivals in places like Florida and Virginia. The catch is that tougher competition, heavy costs, and ongoing federal limits could squeeze profits and make it harder to fund growth.Read more

Green Thumb Industries is pushing into newly legal cannabis markets and rolling out new products, but a messy patchwork of rules and a crowded market could make growth harder than it looks. See why oversupply, rising costs, and shifting state decisions may test the company’s resilience even as demand keeps expanding.Read more

Knight Therapeutics sells prescription drugs across Canada and Latin America, but growing pressure on medicine pricing and tougher competition could squeeze profits. Its dependence on licensed products and exposure to unstable markets may make results more unpredictable than many investors expect.Read more

Curaleaf is pushing into new markets, but tougher rules and falling prices could make it harder to keep profits from slipping. See why Europe’s promise may not be enough to protect the business, and what could still turn the story around.Read more

DRI Healthcare Trust aims to grow by collecting royalty payments from medicines, and it’s starting to secure deals earlier in a drug’s life as new launches come to market. The upside is steadier cash coming in and fewer shares over time, but competition for deals and shifting drug pricing rules could make results less predictable.Read more